<DOC>
	<DOCNO>NCT01364792</DOCNO>
	<brief_summary>This one-week , randomize , double blind add-on study valaciclovir versus placebo 24 clinical patient Schizophrenia accord DSM IV , currently experience psychosis define positive item Positive Negative Syndrome Scale ( PANNS ) score , five high one item four two item scale . Each patient randomize double blind treatment either valaciclovir placebo one week . The main objective find pre- post-valaciclovir treatment difference hippocampal inflammation , measure positron emission tomography . The secondary objective improve cognition suppose anti-inflammatory effect hippocampus valaciclovir . This measure pre- post-treatment performance PANSS , attention memory test . Both treatment team patient remain blind course study . Following active treatment phase , patient receive treatment clinically indicate .</brief_summary>
	<brief_title>To Rescue Cognition With Valaciclovir</brief_title>
	<detailed_description>Rationale : Schizophrenia chronic disable brain disease , unknown aetiology . Recently , show presence inflammatory process hippocampus schizophrenic patient psychosis . In addition , find evidence presence herpes viruses temporal lobe schizophrenic patient psychosis . Taken together , hypothesize hippocampal inflammation cause presence herpes virus , inflammation interferes normal involvement hippocampus cognition . Anti-viral treatment , valaciclovir , reduce activity herpes virus hippocampus could reduce neuroinflammation thus improve cognition symptom schizophrenia . Objective : The main objective find pre- post-valaciclovir treatment difference hippocampal inflammation , measure positron emission tomography , schizophrenic patient expose psychotic episode . The secondary objective improve cognition suppose anti-inflammatory effect hippocampus valaciclovir . Study design : The study double-blind randomize placebo-controlled trial . Study population : For study , 24 male patient compliant schizophrenia disorder ( DSM-IV cod 295.xx ) include psychosis . The age 18 patient ethnic background include . Intervention ( applicable ) : Of 24 included patient , 12 patient receive 8 g ( 4x2 g per day ) valaciclovir daily period 7 consecutive day 12 patient receive 8 g ( 4x2 g per day ) placebo daily 7 consecutive day . Main study parameters/endpoints : The main study parameter pre-and post-treatment [ 11C ] -PK11195 bind potential ( inflammatory marker ) hippocampus , pre- post-treatment performance PANSS , attention , memory IQ test . Nature extent burden risk associate participation , benefit group relatedness : Patients admit psychiatric hospital , already admit part regular treatment , treat valaciclovir seven consecutive 24-h period . Patients fill questionnaire undergo part Schedules Clinical Assessment Neuropsychiatry ( SCAN ) interview MRI scan , undergo PANSS interview , attention , memory IQ test , PET scan twice . A total 345 ml blood take determination kidney liver function , herpes virus antibody , acyclovir level blood PET scan data-analysis . Treatment valaciclovir may cause nausea headache risk serious side effect low ( &lt; 1 10.000 ) . For PET scan , arterial catheterization cause discomfort patient expose radioactivity minor moderate risk . The patient treat valaciclovir direct benefit form treatment , may reduce symptom . In general , study find evidence involvement herpes viruses schizophrenia , lead improve treatment patient near future .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Age 18 Written inform consent participation Diagnosis : schizophrenia , subtypes ( DSMIV 295.xx ) Psychosis , characterise total score positive scale PANSS 14 . In addition , minimal score 4 item positive scale . The use benzodiazepine . Benzodiazepines affinity peripheral benzodiazepine receptor target receptor [ 11C ] PK11195 PET thus interfere PET study . The use nonsteroidal antiinflammatory drug paracetamol week PET scan treatment valaciclovir The use anticoagulants coagulation disorder Use somatic medication may affect immune system ( e.g . corticoid , antiinflammatory drug , immune suppressive drug ) Use investigational drug Current recent ( &lt; 1 year ) alcohol substance abuse Disturbed kidney function Disturbed liver function Current recent ( &lt; 4 week ) infectious inflammatory disease Current systemic disease Major metabolic disease ( diabetes , hyper hypothyroidism , Cushing disease Addison disease ) Somatic , organic neurological disorder Participation scientific research study ( &lt; 1 year ) involve radiation Claustrophobia Presence material body magnetize , like : A pacemaker Metal fragment Shunts Artificial heart valves Vascular clip Fixed hearing aid Tattoos contain metal Hair implant Artificial denture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>treatment</keyword>
	<keyword>inflammation</keyword>
	<keyword>neuroinflammation</keyword>
	<keyword>hippocampal</keyword>
</DOC>